Corxel Pharmaceuticals agreed to go public via a SPAC merger, with plans to advance an oral GLP-1 program into Phase 3, targeting the first half of 2027 for trial initiation. The deal frames oral incretin therapy as a differentiator on tolerability versus existing class approaches. In parallel, the company’s other disclosed GLP-1 and amylin-targeting medicines position it for additional de-risking milestones ahead of later-stage readouts. The transaction signals continued investor appetite for obesity drug development—especially delivery formats designed to broaden adherence and reduce gastrointestinal burden.